Lurasidone Pediatric Bipolar Study

NCT ID: NCT02046369

Last Updated: 2017-12-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 350 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-31
• Study Completion Date: 2016-10-31

Brief Summary

A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression

Detailed Description

This is a randomized, parallel, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of flexibly dosed lurasidone (20 - 80 mg/day) for 6 weeks compared with placebo in children and adolescent subjects with depression associated with Bipolar I Disorder (bipolar depression).

Conditions

Bipolar I Depression

Keywords

Lurasidone, Latuda, Bipolar Depression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Luradisone

Luradisone 20- 80 mg administered once daily

Group Type: EXPERIMENTAL

Lurasidone

Intervention Type: DRUG

Lurasidone flexibly dosed 20-80 mg once daily

Placebo

Placebo administered once daily

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo Comparator once daily

Interventions

Lurasidone

Lurasidone flexibly dosed 20-80 mg once daily

Intervention Type: DRUG

Placebo

Placebo Comparator once daily

Intervention Type: DRUG

Other Intervention Names

Latuda

Eligibility Criteria

Inclusion Criteria

• Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' adherence to the study procedures must be obtained for subjects who are not emancipated. If emancipated, subjects must provide written informed consent. In accordance with Institutional Review Board (IRB) requirements, the subject will complete an informed assent prior to study participation.

• Male or female subjects 10 to 17 years of age, inclusive with bipolar I disorder, most recent episode depressed, with or without rapid cycling disease course (≥ 4 episodes of mood disturbance but < 8 episodes in the previous 12 months) and without psychotic features (diagnosed by DSM-V criteria, and confirmation of the bipolar I disorder diagnosis by an adequately trained clinician at the time of screening, by means of the Schedule for Affective Disorders and Schizophrenia for School-age Children [K-SADS-PL]). Note: The current episode of major depression associated with bipolar I disorder must be confirmed by the investigator and noted in the source records.
• Subject has a lifetime history of at least one manic episode. A reliable informant (eg, family member or caregiver) or medical records must be able to confirm this history.
• Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration.
• CDRS-R score ≥ 45 at screening and Baseline.
• YMRS score ≤ 15 (with YMRS Item 1 [elevated mood] score ≤ 2) at screening and Baseline.
• Within 3rd to 97th percentile for gender specific BMI-for-age growth charts from the World Health Organization (WHO) growth charts
• In good physical health on the basis of medical history, physical examination, and laboratory screening.
• Females who participate in this study:

• are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-
• practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 7 days after the last dose of study drug has been taken; -OR-
• are sexually active and willing to use a medically effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
• Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
• In the judgment of the investigator, the subject is able to swallow the size and number of study drug tablets specified per protocol
• Willing and able to adhere to protocol-specified meal requirements during dosing.
• Subjects may have a lifetime diagnosis of ADHD. If a subject is taking psychostimulants for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study. This must be confirmed by the investigator and noted in the source records.

Exclusion Criteria

• Has an Axis I or Axis II (DSM-IV or any DSM-5) diagnosis other than bipolar I disorder that has been the primary focus of treatment within 3 months of screening.
• Subject has been hospitalized for a bipolar manic or mixed episode within the 30 days prior to randomization.
• Has a history or current diagnosis of intellectual disability, autism spectrum disorder, neuroleptic malignant syndrome, or any neurologic disorder, or severe head trauma.
• Lifetime history of human immunodeficiency virus (HIV) positive or acquired immune deficiency syndrome (AIDS), or history of Hepatitis B or C.
• Any of the following:
• Documented history of chromosomal disorder with developmental impairment (ie, trisomy chromosome 21; 22q11 deletion syndrome).
• Evidence of any chronic organic disease of the CNS such as tumors, inflammation, active seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood - eg, Duchenne muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders. In addition, subjects must not have a history of persistent neurological symptoms attributable to serious head injury. Past history of febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is not exclusionary.
• CDRS-R total score > 85 at screening or Baseline
• Demonstrates a decrease (improvement) of ≥ 25% in the CDRS-R adjusted total score between Screening and Baseline visits, or the CDRS-R is below 45 at Baseline.
• Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.
• Lifetime history of electroconvulsive therapy (ECT).
• Resistant to antipsychotic treatment based on at least two prior adequate trials (ie, adequate dose and duration) of an antipsychotic agent within the current episode of depression, or subject has a history of non-response to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode.
• Clinically significant neurological, metabolic (including Type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, carcinoma, and/or urological disorder that would pose a risk to the subjects if they were to participate in the study or that might confound the results of the study.
• Has a history of malignancy < 5 years prior to signing the informed consent.
• Clinically significant finding(s) on physical examination determined by the investigator to pose a health concern to the subject while on study.
• Clinically relevant abnormal laboratory values or abnormal vital sign values/findings.
• A history or presence of abnormal ECG, which in the investigator's opinion is clinically significant. Abnormal screening ECGs will be centrally over-read, and eligibility will be determined based on the over-read.
• Presence or history (within the last year) of a medical or surgical condition (eg, gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
• Clinically significant substance abuse disorder (with the exception of caffeine or tobacco) based on DSM-5 criteria within the last 6 months prior to screening.
• Positive test results at screening or Baseline for:

1. Urine drugs of abuse (including amphetamines/methamphetamines, barbiturates, benzodiazepines, cocaine, opioids, phencyclidine, and cannabinoids). A positive test for amphetamines/methamphetamines, barbiturates, opioids, or benzodiazepines may not result in exclusion of subjects if the investigator determines that the positive test is as a result of taking prescription medicine(s) as prescribed. In the event a subject tests positive for cannabinoids (tetrahydrocannabinol), the investigator will evaluate the subject's ability to abstain from prohibited substances during the study. If in the investigator's clinical judgment the subject will abstain, the subject may be enrolled after consultation with the Medical Monitor.

2. Pregnancy test.

• Females who are pregnant, lactating, or likely to become pregnant during the study.
• Participated in another interventional clinical trial or receiving an investigational product within 30 days prior to screening.
• Donation of whole blood within 60 days prior to randomization.
• Known history or presence of clinically significant intolerance to any antipsychotic medications including but not limited to angioedema, serotonin or neuroleptic malignant syndromes.
• Clinically relevant history of drug hypersensitivity to lurasidone or any components in the formulation.
• Use of concomitant medications that consistently prolong the QT/QTc interval within 28 days prior to randomization.
• Received depot neuroleptics unless the last injection was at least 1 month or 1 treatment cycle prior to screening, whichever is longer.
• Received treatment with antidepressants, atomoxetine or alpha 2 agonists (eg, guanfacine) within 3 days prior to randomization, fluoxetine hydrochloride within 21 days of randomization, monoamine oxidase (MAO) inhibitor within 28 days of randomization, or clozapine within 120 days of randomization.
• Use of all psychotropic medications prior to randomization with the exception of those medications explicitly permitted within 3 days prior to randomization (7 days prior to randomization for aripiprazole).
• Has a prolactin concentration ≥ 100 ng/mL at screening, or has a history of pituitary adenoma.
• At screening or Baseline the subject answers "yes" to "Suicidal Ideation" Items 4 or 5 on the C-SSRS or has a score of 7 on item 13, Suicidal Ideation, on the CDRS-R.
• Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property during the study. Subject has a history of one or more serious suicide attempts (based on the investigator's judgment) in the 3 months prior to screening. Subjects determined to be at risk of suicide or injury, as assessed by the investigator at screening, will be referred for further psychiatric evaluation.
• Adhering to a special diet for the 28 days prior to drug administration (eg, liquid, protein, raw food diet).
• Subject is planning to move during the study, is chronically homeless, or is unable to attend all planned study visits. The Medical Monitor will be consulted for individual cases, as needed.
• Subject with newly diagnosed Type 2 diabetes during screening or subject is on injectable medication for the treatment of Type 2 diabetes. A subject with Type 2 diabetes is eligible for study inclusion if considered clinically stable, which is defined as:

• Random (non-fasting) screening glucose is < 200 mg/dl (11.1 mmol/L); and If ≥ 200 mg/dL (11.1 mmol/L) must be retested in a fasted state. Retested fasted value cannot be ≥ 126 mg/dL.
• HbA1c ≤ 6.5%; and
• If a subject is currently being treated with oral anti-diabetic medication(s), the dose must have been stable for at least 4 weeks prior to screening. Such medication may be adjusted or discontinued during the study, as clinically indicated.
• Subject has required hospitalization for diabetes or related complications in the past 12 months.
• The use of concomitant medications that are potent inducers or inhibitors of the cytochrome P450 (CYP) 3A4 enzyme system during the trial (from signing informed consent until follow-up).
• Clinically significant orthostatic hypotension (ie, a drop in systolic blood pressure of 20 mmHg or more and/or drop in diastolic blood pressure of 10 mmHg or more within 4 minutes of standing up).

• Minimum Eligible Age: 10 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sumitomo Pharma America, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director, MD

Role: STUDY_DIRECTOR

Sumitomo Pharma America, Inc.

Locations

Harmonex Neuroscience Research

Dothan, Alabama, United States

ProScience Research Group

Culver City, California, United States

Hartford Hospital

Hartford, Connecticut, United States

Sarkis Clinical Trials - Parent

Gainesville, Florida, United States

APG Research, LLC

Orlando, Florida, United States

Atlanta Center for Medical Research

Atlanta, Georgia, United States

Attalla Consultants, LLC

Smyrna, Georgia, United States

Capstone Clinical Research, Inc.

Libertyville, Illinois, United States

Psychiatric Associates

Overland Park, Kansas, United States

Lake Charles Clinical Trials, LLC

Lake Charles, Louisiana, United States

Kennedy Krieger Institute

Baltimore, Maryland, United States

Neurobehavioral Medicine Group, PLLC

Bloomfield Hills, Michigan, United States

St. Charles Psychiatric Associates

Saint Charles, Missouri, United States

Jersey Shore University Medical Center

Neptune City, New Jersey, United States

North Shore/Long Island Jewish PRIME

Glen Oaks, New York, United States

Bioscience Research, LLC

Mount Kisco, New York, United States

Finger Lakes Clinical Research

Rochester, New York, United States

Richmond Behavioral Associates

Staten Island, New York, United States

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

University Hospitals Case Medical Center

Cleveland, Ohio, United States

Cutting Edge Research of Enid

Oklahoma City, Oklahoma, United States

Research Strategies of Memphis, LLC

Memphis, Tennessee, United States

BioBehavioral Research of Austin

Austin, Texas, United States

Pillar Clinical Research, LLC

Dallas, Texas, United States

Family Psychiatry of The Woodlands, P.A.

The Woodlands, Texas, United States

Ericksen Research & Development, LLC

Clinton, Utah, United States

Aspen Clinical Research

Orem, Utah, United States

University of Virginia

Charlottesville, Virginia, United States

Clinical Research Partners, LLC

Petersburg, Virginia, United States

Pacific Institute Of Medical Sciences

Bothell, Washington, United States

MHC - Ruse, EOOD

Rousse, , Bulgaria

MHAT-Targovishte, AD

Targovishte, , Bulgaria

DCC "Mladost M" - Varna, OOD

Varna, , Bulgaria

Centro de Investigaciones y Proyectos en Neurociencias CIPNA

Barranquilla, , Colombia

Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda

Bogotá, , Colombia

Hôpitaux Pédiatriques de Nice CHU-Lenval

Nice, Alpes Maritimes, France

CHU Nantes - Hôpital Mère-Enfant

Nantes, , France

Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert

Budapest, , Hungary

Bekes Megyei Pandy Kalman Korhaz

Gyula, , Hungary

Accelerium S. de R.L. de C.V.

Monterrey, Nuevo León, Mexico

Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C.

Culiacán, , Mexico

Instituto de Investigaciones Aplicadas a la Neurociencia A.C.

Durango, , Mexico

Instituto de Informacion de Investigacion en Salud Mental

Monterrey, , Mexico

Consultorio Especializado Psiquiatría Infantil y Adolescentes

San Luis Potosí City, , Mexico

West Visayas State University Medical Center

Iloilo City, , Philippines

National Center for Mental Health

Mandaluyong, , Philippines

Veterans Memorial Medical Center

Quezon City, , Philippines

NZOZ Poradnia Zdrowia Psychicznego

Kobierzyce, , Poland

Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu

Torun, , Poland

Instytut Psychiatrii i Neurologii

Warsaw, , Poland

INSPIRA Clinical Research

San Juan, , Puerto Rico

Chonbuk National University Hospital

Jeonju, Jeollabuk-do, South Korea

Chonnam National University Hospital

Gwangju, Jeollanam-do, South Korea

Inha University Hospital

Incheon, , South Korea

Seoul National University Bundang Hospital

Seongnam-si, , South Korea

Seoul National University Hospital

Seoul, , South Korea

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU

Ivano-Frankivsk, , Ukraine

SI Institute of Neurology, Psychiatry and Narcology of NAMSU

Kharkiv, , Ukraine

SI Institute of Children and Adolescents Healthcare of NAMSU

Kharkiv, , Ukraine

CI Kherson Regional Psychiatric Hospital of Kherson RC

Kherson, , Ukraine

CI Lviv Regional Clinical Psychiatric Hospital

Lviv, , Ukraine

CI Odesa Regional Medical Center of Mental Health

Odesa, , Ukraine

O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy

Poltava, , Ukraine

Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU

Ternopil, , Ukraine

Chair of Psychiatry and Narcology, Vinnytsia National Medical University, O.I. Yushchenko Regional Psychoneurological Hospital

Vinnytsia, , Ukraine

Countries

United States; Bulgaria; Colombia; France; Hungary; Mexico; Philippines; Poland; Puerto Rico; South Korea; Ukraine

References

DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. J Am Acad Child Adolesc Psychiatry. 2017 Dec;56(12):1015-1025. doi: 10.1016/j.jaac.2017.10.006. Epub 2017 Oct 13.

Reference Type: DERIVED

PMID: 29173735 (View on PubMed)

Other Identifiers

2013-004903-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D1050326

Identifier Type: -

Identifier Source: org_study_id